2022³â ´ëÇÑ¿ä·Î»ý½Ä±â°¨¿°ÇÐȸ ¿öÅ©¼¥: Themicrobiomeinurologicaldiseases : 2022-02-19±³À°ÀÏÀÚ : 2022-02-19
±³À°Àå¼Ò : ¿©¼ö À¯Å¾¸¶¸®³ªÈ£ÅÚ 2Ãþ ±×¸®´ÏġȦ
±³À°ÁÖÁ¦ :
2022³â ´ëÇÑ¿ä·Î»ý½Ä±â°¨¿°ÇÐȸ ¿öÅ©¼¥: ThemicrobiomeinurologicaldiseasesÁÖÃÖ±â°ü : ´ëÇѺñ´¢ÀÇÇÐȸ(19.2 ¸íĪº¯°æ ´ëÇѺñ´¢±â°úÇÐȸ)
½ÃÇà±â°ü(ÁöºÎ/°ú) : ´ëÇÑ¿ä·Î»ý½Ä±â°¨¿°ÇÐȸ
´ã´çÀÚ : ¿ä·Î»ý½Ä±â°¨¿°ÇÐȸ
¿¬¶ôó : 02-2038-7988
À̸ÞÀÏ :
gaonpco@gaonpco.com ±³À°Á¾·ù : ºñ´¢ÀÇÇаú
Âü¼®¿¹»óÀοø : 50¸í
Èñ¸ÁÆòÁ¡ : 4Á¡
Áö¿ª :
Àü¶ó³²µµ±³À°½Ã°£ : 4 ½Ã°£ 50ºÐ
¼¼ºÎ¼ö°·á : 100,000¿ø
ºñ°í ȸ¿ø(¿¬È¸ºñ ³³ºÎ): ¹«·á ȸ¿ø(¿¬È¸ºñ ¹Ì³³): 10,000¿ø ºñȸ¿ø: 100,000¿ø Àü°øÀÇ ¹× °£È£»ç: ¹«·á
±¸ºÐ ¿ùÀÏ °ÀÇ½Ç ½Ã°£ ±³À°Á¦¸ñ °»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±³À°½Ã°£ 02-19 À¯Å¾¸¶¸®³ªÈ£ÅÚ 2Ãþ ±×¸®´ÏÄ¡ Ȧ 10:00~10:15 Dysbiosis & SCFA: Mechanisms and Functional Importance in the Gut. ±èÈ«¿í(°Ç¾çÀÇ´ë)
±³À°½Ã°£ 02-19 À¯Å¾¸¶¸®³ªÈ£ÅÚ 2Ãþ ±×¸®´ÏÄ¡ Ȧ 10:15~10:30 SCFA & Urological Disease (Dysbiosis in Urological Diseases : e.g BPS/IC, UUI/OAB, CP/CPPS, Stone, Prostate Cancer, Bladder Cancer) ¾çÈñÁ¶(¼øõÇâÀÇ´ë)
±³À°½Ã°£ 02-19 À¯Å¾¸¶¸®³ªÈ£ÅÚ 2Ãþ ±×¸®´ÏÄ¡ Ȧ 10:30~10:45 Polyphenol as Modulators of Gut Microbiota Dysbiosis (in the context of prostate health) °íÇõÁØ(µ¿¾ÆÀÇ´ë)
Åä·Ð 02-19 À¯Å¾¸¶¸®³ªÈ£ÅÚ 2Ãþ ±×¸®´ÏÄ¡ Ȧ 10:45~11:00 Panel Discussion ¹Î½Â±â(°ñµå¸¸ºñ´¢ÀÇÇаú)
±³À°½Ã°£ 02-19 À¯Å¾¸¶¸®³ªÈ£ÅÚ 2Ãþ ±×¸®´ÏÄ¡ Ȧ 11:00~11:20 Human genome project & next generation sequencing À̱æÈ£(´Ü±¹ÀÇ´ë)
±³À°½Ã°£ 02-19 À¯Å¾¸¶¸®³ªÈ£ÅÚ 2Ãþ ±×¸®´ÏÄ¡ Ȧ 11:20~11:40 Microbiome Diagnostics (16S ribosomal RNA, whole genome sequencing) À̹̰æ(Áß¾ÓÀÇ´ë Áø´Ü°Ë»çÀÇÇаú)
ÈÞ½Ä 02-19 11:40~11:50 Coffee Break ()
±³À°½Ã°£ 02-19 À¯Å¾¸¶¸®³ªÈ£ÅÚ 2Ãþ ±×¸®´ÏÄ¡ Ȧ 11:50~12:05 Male Bladder Microbiome Relates to Lower Urinary Tract Symptoms Á¤½ÂÀÏ(Àü³²ÀÇ´ë)
±³À°½Ã°£ 02-19 À¯Å¾¸¶¸®³ªÈ£ÅÚ 2Ãþ ±×¸®´ÏÄ¡ Ȧ 12:05~12:20 Impact of Covid-19 on LUTS in Patients with BPH ÃÖÁß¿ø(Áß¾Óº¸Èƺ´¿ø)
Åä·Ð 02-19 À¯Å¾¸¶¸®³ªÈ£ÅÚ 2Ãþ ±×¸®´ÏÄ¡ Ȧ 12:20~12:35 Panel Discussion ¹ÚÈïÀç(¼º±Õ°üÀÇ´ë)
½Ä»ç 02-19 12:35~13:20 Lunch ()
±³À°½Ã°£ 02-19 À¯Å¾¸¶¸®³ªÈ£ÅÚ 2Ãþ ±×¸®´ÏÄ¡ Ȧ 13:20~13:35 Biofilm and Quorum Sensing Inhibitors ÃÖÇö¼·(°¡Å縯ÀÇ´ë)
ÈÞ½Ä 02-19 À¯Å¾¸¶¸®³ªÈ£ÅÚ 2Ãþ ±×¸®´ÏÄ¡ Ȧ 13:35~13:50 Bacteriophage-Derived Endolysins to Target Gram-Negative Bacteria. À¯¼ºÇö(Àü³²ÀÇ´ë)
Åä·Ð 02-19 À¯Å¾¸¶¸®³ªÈ£ÅÚ 2Ãþ ±×¸®´ÏÄ¡ Ȧ 13:50~14:05 Panel Discussion ÀåÀÎÈ£(Áß¾ÓÀÇ´ë)
±³À°½Ã°£ 02-19 À¯Å¾¸¶¸®³ªÈ£ÅÚ 2Ãþ ±×¸®´ÏÄ¡ Ȧ 14:05~14:20 FMT for Recurrent Cystitis ±è¿¬ÁÖ(´ë±¸ÆÄƼ¸¶º´¿ø)
±³À°½Ã°£ 02-19 À¯Å¾¸¶¸®³ªÈ£ÅÚ 2Ãþ ±×¸®´ÏÄ¡ Ȧ 14:20~14:35 Effect of ICU Catheter Management by Urologists on the Occurrence and Prevention of CAUTI ¹è»ó¶ô(°¡Å縯ÀÇ´ë)
Åä·Ð 02-19 À¯Å¾¸¶¸®³ªÈ£ÅÚ 2Ãþ ±×¸®´ÏÄ¡ Ȧ 14:35~14:50 Panel Discussion À̽ÂÁÖ(°¡Å縯ÀÇ´ë)
ÈÞ½Ä 02-19 14:50~15:00 Coffee Break ()
±³À°½Ã°£ 02-19 À¯Å¾¸¶¸®³ªÈ£ÅÚ 2Ãþ ±×¸®´ÏÄ¡ Ȧ 15:00~15:15 Urinary tract infections in patients underwent radical cystectomy with urinary diversion ÀÌÁÖ¿ë(¿¬¼¼ÀÇ´ë)
±³À°½Ã°£ 02-19 À¯Å¾¸¶¸®³ªÈ£ÅÚ 2Ãþ ±×¸®´ÏÄ¡ Ȧ 15:15~15:30 Antibiotic Stewardship and Postoperative Infections in Urethroplasties ¹Ú¹Î±¸(ÀÎÁ¦ÀÇ´ë)
±³À°½Ã°£ 02-19 À¯Å¾¸¶¸®³ªÈ£ÅÚ 2Ãþ ±×¸®´ÏÄ¡ Ȧ 15:30~15:45 Manangement of Fournier Gangrene (Reconstruction of Defects After Fournier Gangrene ; skin grafts vs flaps) ÀÌÁ¤¿ì(°æÈñÀÇ´ë)
Åä·Ð 02-19 À¯Å¾¸¶¸®³ªÈ£ÅÚ 2Ãþ ±×¸®´ÏÄ¡ Ȧ 15:45~16:10 Panel Discussion ³ª¿õ(±¹¸³Áß¾ÓÀÇ·á¿ø)